SV2005002129A - NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A - Google Patents
NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360AInfo
- Publication number
- SV2005002129A SV2005002129A SV2005002129A SV2005002129A SV2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A
- Authority
- SV
- El Salvador
- Prior art keywords
- sexual
- disorder
- disorders
- compounds
- dysfunction
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 2
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 2
- 206010002652 Anorgasmia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000030047 Sexual desire disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 1
- 229940052760 dopamine agonists Drugs 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 230000005284 excitation Effects 0.000 abstract 1
- 208000014840 female orgasmic disease Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 201000004197 inhibited female orgasm Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE FORMULA (I): (VER FORMULA) QUE SON UNA CLASE DE AGONISTAS DE DOPAMINA, MAS PARTICULARMENTE UNA CLASE DE AGONISTAS QUE SON SELECTIVOS PARA D3 SOBRE D2. ESTOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE LA DISFUNCION SEXUAL, POR EJEMPLO LA DISFUNCION SEXUAL FEMENINA (FSD), EN PARTICULAR EL TRASTORNO DE LA EXCITACION SEXUAL FEMENINA (FSAD), TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERES EN EL SEXO), TRASTORNO ORGASMICO FEMENINO (FOD; INCAPACIADAD PARA ALCANZAR EL ORGASMO); Y LA DISFUNCION SEXUAL MASCULINA, EN PARTICULAR LA DISFUNCION ERECTIL MASCULINA (MED). LA DISFUNCION SEXUAL MASCULINA SEGUN SE REFIERE EN LA PRESENTE MEMORIA SE SUPONE QUE INCLUYE TRASTORNOS EYACULATORIO TALES COMO EYACULACION PRECOZ, ANORGASMIA (INCAPACIDAD PARA ALCANZAR EL ORGASMO) O TRASTORNOS DEL DESEO TALES COMO EL TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERES EN EL SEXO). ESTOS COMPUESTOS TAMBIEN SON UTILES PARA TRATAR TRASTORNOS NEUROPSIQUIATRICOS Y TRASTORNOS NEURODEGENERATIVOSTHIS INVENTION PROVIDES FORMULA COMPOUNDS (I): (SEE FORMULA) THAT ARE A CLASS OF DOPAMINE AGONISTS, MORE PARTICULARLY A CLASS OF AGONISTS THAT ARE SELECTIVE FOR D3 ON D2. THESE COMPOUNDS ARE USEFUL FOR THE TREATMENT AND / OR PREVENTION OF SEXUAL DYSFUNCTION, FOR EXAMPLE THE FEMALE SEXUAL DYSFUNCTION (FSD), IN PARTICULATE THE FEMALE SEXUAL EXCITATION DISORDER (FSAD), THE HIPO-SEXUAL SEXUAL DESIRE DISORDER (HIPOACD); IN THE SEX), FEMALE ORGASMIC DISORDER (FOD; INABILITY TO REACH ORGASM); AND THE MALE SEXUAL DYSFUNCTION, IN PARTICULAR THE MALE ERECTILE DYSFUNCTION (MED). THE MALE SEXUAL DYSFUNCTION AS REFERRED TO IN THIS REPORT IS ASSUMED THAT IT INCLUDES EJACULATORY DISORDERS SUCH AS EFFECTIVE EJACULATION, ANORGASMIA (INABILITY TO ACHIEVE THE ORGASM) OR DISASTER DISORDERS OF SUCH AS THE DISORDER IN THE HALF; SEX). THESE COMPOUNDS ARE ALSO USEFUL TO TREAT NEUROPSYCHIATRIC DISORDERS AND NEURODEGENERATIVE DISORDERS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
| GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2005002129A true SV2005002129A (en) | 2005-12-13 |
Family
ID=34970000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2005002129A SV2005002129A (en) | 2004-05-27 | 2005-05-27 | NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1758862A1 (en) |
| JP (1) | JP4198183B2 (en) |
| AP (1) | AP2006003824A0 (en) |
| AR (1) | AR049548A1 (en) |
| AU (1) | AU2005247699A1 (en) |
| BR (1) | BRPI0511571A (en) |
| CA (1) | CA2567935C (en) |
| EA (1) | EA200601982A1 (en) |
| EC (1) | ECSP067029A (en) |
| GT (1) | GT200500125A (en) |
| IL (1) | IL179314A0 (en) |
| MA (1) | MA28607B1 (en) |
| MX (1) | MXPA06013786A (en) |
| NL (1) | NL1029139C2 (en) |
| NO (1) | NO20065326L (en) |
| PA (1) | PA8635101A1 (en) |
| PE (1) | PE20060366A1 (en) |
| SV (1) | SV2005002129A (en) |
| TW (1) | TW200609216A (en) |
| UY (1) | UY28925A1 (en) |
| WO (1) | WO2005115985A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| CA2752105C (en) * | 2009-02-13 | 2017-10-31 | Matthias Vennemann | Fused pyrimidines |
| EP2558437B1 (en) * | 2010-04-12 | 2015-08-05 | Supernus Pharmaceuticals, Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
| US9504949B2 (en) | 2011-06-30 | 2016-11-29 | Donaldson Company, Inc. | Air/oil separator assemblies; components; and methods |
| GB2543296A (en) * | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| HRP20241015T1 (en) | 2016-07-20 | 2024-11-08 | Novartis Ag | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS |
| IL274868B2 (en) * | 2017-12-08 | 2024-06-01 | Boehringer Ingelheim Int | Imidazopyridine derivatives and the use thereof as medicament |
| US12479838B2 (en) * | 2019-04-12 | 2025-11-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
| MX2022006176A (en) | 2019-11-22 | 2022-08-17 | Incyte Corp | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR. |
| PH12022553501A1 (en) | 2020-06-16 | 2024-04-22 | Incyte Corp | Alk2 inhibitors for the treatment of anemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| NZ540505A (en) * | 2002-12-10 | 2007-02-23 | Pfizer | Morpholine derivatives for use as dopamine agonists in the treatment of I.A. sexual dysfunction |
-
2005
- 2005-05-17 CA CA002567935A patent/CA2567935C/en not_active Expired - Fee Related
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/en not_active Expired - Fee Related
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 EA EA200601982A patent/EA200601982A1/en unknown
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/en unknown
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/en not_active Application Discontinuation
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/en not_active Application Discontinuation
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/en not_active Ceased
- 2005-05-17 EP EP05747191A patent/EP1758862A1/en not_active Withdrawn
- 2005-05-24 GT GT200500125A patent/GT200500125A/en unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/en not_active Application Discontinuation
- 2005-05-26 NL NL1029139A patent/NL1029139C2/en not_active IP Right Cessation
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/en unknown
- 2005-05-26 AR ARP050102169A patent/AR049548A1/en unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/en not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/en unknown
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/en not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/en unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/en unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY28925A1 (en) | 2005-12-30 |
| AU2005247699A1 (en) | 2005-12-08 |
| GT200500125A (en) | 2006-01-10 |
| NO20065326L (en) | 2006-12-19 |
| PA8635101A1 (en) | 2006-05-16 |
| JP4198183B2 (en) | 2008-12-17 |
| WO2005115985A1 (en) | 2005-12-08 |
| BRPI0511571A (en) | 2008-01-02 |
| JP2008500331A (en) | 2008-01-10 |
| AP2006003824A0 (en) | 2006-12-31 |
| AR049548A1 (en) | 2006-08-16 |
| ECSP067029A (en) | 2006-12-29 |
| EP1758862A1 (en) | 2007-03-07 |
| IL179314A0 (en) | 2007-03-08 |
| CA2567935A1 (en) | 2005-12-08 |
| PE20060366A1 (en) | 2006-05-15 |
| TW200609216A (en) | 2006-03-16 |
| MA28607B1 (en) | 2007-05-02 |
| MXPA06013786A (en) | 2007-01-25 |
| CA2567935C (en) | 2009-10-27 |
| NL1029139C2 (en) | 2006-06-19 |
| EA200601982A1 (en) | 2007-04-27 |
| NL1029139A1 (en) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000978A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| CL2017001426A1 (en) | New compounds of 3-substituted 5-amino-6h-thiazolo [4,5-d] pyrimidin-2,7-dione for the treatment and prophylaxis of viral infections. | |
| CL2017003404A1 (en) | Antibacterial compounds | |
| CL2017001459A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| DOP2016000208A (en) | BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS | |
| MX391859B (en) | Combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| CL2016000341A1 (en) | Methods to treat myositis by sporadic inclusion bodies | |
| CO6430487A2 (en) | ANTI-HER ANTIBODIES | |
| MX2017010845A (en) | Anti-dll3 chimeric antigen receptors and methods of use. | |
| UY35682A (en) | ANTI-ACTIVINE ANTIBODIES A AND USES OF THE SAME | |
| CL2015002675A1 (en) | CFR mRNA compositions and related methods and uses | |
| PE20190973A1 (en) | TETRAHYDROPIRAZOLOPIRIMIDINE COMPOUNDS | |
| MX2019009908A (en) | COMBINATION OF A PPAR AGONIST WITH AN FXR AGONIST. | |
| CL2017001718A1 (en) | Glucagon derivatives with improved stability | |
| CL2019003670A1 (en) | Composition comprising mannose oligosaccharide and process to make it and use of it. | |
| SV2005002129A (en) | NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A | |
| MX2018005589A (en) | COMPOSITIONS THAT INCLUDE ANTIBODIES AGAINST IL6R FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA, AND METHODS OF USE OF THE SAME. | |
| CR20150496A (en) | NEW INHIBITING COMPOUNDS OF TYPE 10A PHOSPHODIESTERASE | |
| BR112016000431A8 (en) | compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist | |
| AR100444A1 (en) | USE OF PALMITOYLETHANOLAMIDE IN OPIOID COMBINATION | |
| MX2015005734A (en) | METHODS OF TREATMENT OF HEPATIC DISEASES. | |
| CL2015003460A1 (en) | Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for the treatment of an ophthalmic disease | |
| CU20150176A7 (en) | DERIVATIVES OF SUPPLY OF SUBSTITUTED TRIAZOLPIRIDINES | |
| CY1120178T1 (en) | TREATMENT OF MENOPAUSAL EXTRACTS WITH ROPINIROL AND TIZANIDINE | |
| MX2022000356A (en) | COMPOUND FOR COMBINATION TREATMENT. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |